1. Home
  2. > Pharmaceutical
  3. > Therapy Market Trends
China Human Vaccine Industry Report, 2020-2026

China Human Vaccine Industry Report, 2020-2026

  • July 2020
  • 213 pages
  • ID: 512477
  • Format: PDF
  • Research In China

Summary

Table of Contents

In China, the lot release for human vaccines plunged by 17.7% in 2018 when the production record fraud of rabies vaccines for human use, freeze-dried by Changsheng Bio-Technology was exposed. The impact fades away amid tighter control on human vaccines in China. In 2019, National Institutes for Food and Drug Control (NIFDC) approved 570 million doses of human vaccine with a year-on-year increase of 5.4%, among which there was more lot release volume of diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed), recombinant Hepatitis B vaccine, and rabies vaccine for human use (freeze-dried), together sharing 33.9% of the total.

The Chinese human vaccine market is now occupied by local companies, where the state-owned enterprises command more than a half of the market. In the first half of 2020, the players had more lot releases, such as China National Biotec Group (CNBG), Institute of Medical Biology, Chinese Academy of Medical Sciences, Walvax Biotechnology, Amy Biotech & Vaccine, Liaoning Cheng Da, NCPC GeneTech Biotechnology, and Sinovac Biotech, holding a combined 82.2% of the total. Noticeably, CNBG takes a lion’s share 43.3%, leading the pack in the industry.

Although the Chinese human vaccine market is ruled by local companies, the imported vaccines are largely the extra EPI vaccines (not free, and residents can choose whether they want to be inoculated) such as 13-valent pneumonia vaccine, HPV vaccine and DTaP-IPV/Hib vaccine. Yet, the 13-valent pneumonia vaccine of Walvax Biotechnology and the 2-valent pneumonia vaccine of Xiamen Innovax Biotech are approved successively for general availability in the market, challenging the overseas vaccine giants at their games and scrambling for more market shares by price advantage, accompanied by the to-be-soon-launched vaccines like 13-valent pneumonia vaccine of Shenzhen Kangtai Biological Products Co., Ltd., 2-valent/9-valent HPV vaccines of Walvax Biotechnology, 4-valent influenza vaccine and 15-valent pneumonia vaccine of Chongqing Zhifei Biological Products Co., Ltd.

The devastating COVID-19 in more than 100 countries causes a total of over 14.77 million cases infected and approximately 609,000 deaths. The mortality rate is high up to 4.1% and the overriding research about coronavirus vaccine and clinical trials get under way.

In at least 200 coronavirus vaccine programs worldwide to date, China stays ahead temporarily in the R&D progress. Seven coronavirus vaccines are in the clinical phase, and Ad5-nCoV, an adenovirus vaccine being co-developed by CanSino Biologics, Inc. and the team led by the academician Chen Wei at the Biological Engineering Institute of Academy of Military Medical Sciences, is advancing faster as its phase-III clinical trials are in place. To curb the pandemic, the related authorities of China will accelerate the examination and approval process for a shorter development cycle and a faster launch to save lives.

Highlights of this report:
Human vaccine industry in China (environments, status quo, market demand, market size, import & export, competition pattern);
Human vaccine market segments in China (market demand, lot releases, competitive landscape);
22 human vaccine companies (operation, vaccine business, etc.)
Conclusions and development tendencies

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

DTP Vaccines Global Market Report 2023

  • $ 5000
  • February 2023
  • 250 pages

Major players in the DTP vaccines market are Merck & Co, Sanofi, GSK, Lanzhou Institute of Biological Products, Novartis AG, Pfizer Inc, Johnson & Johnson, Seqirus, AJ Vaccines, and Bionet-Asia. The global ...

  • World
  • Vaccine
  • Infectious Disease
  • Industry analysis

ref:plp2020

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on